NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Zucara Therapeutics Inc.

Zucara Therapeutics Inc.

Private
TorontoHealthcare & Life Scienceshttps://www.zucara.ca/

Last Round

Series B

May 1, 2025

Total Funding Raised

$52.76M

Company Overview

Zucara Therapeutics Inc. is a biotechnology company developing ZT-01, a first-in-class, once-daily therapeutic to prevent hypoglycemia in people with Type 1 and other insulin-dependent types of diabetes.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

hypoglycemia preventionclinical-stage biotechdiabetes drug developmentType 1 DiabetesT1Dfirst-in-class therapeuticsomatostatin inhibitorinsulin-induced hypoglycemiabiopharmaglucagon responsenocturnal hypoglycemiaPhase 2 clinical trialdrug licensingType 2 DiabetesT2D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Zucara Therapeutics Inc. Comps

Public and private peers based on sector, stage, and business model.

Zucara Therapeutics Inc. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Zucara Therapeutics Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 1, 2025
GrantJun 15, 2023
GrantMay 2, 2022
GrantNov 2, 2020
Series AMar 31, 2020
Grant
Jul 12, 2019

Key People

Founding team and executive leadership

Richard Liggins

Co Founder & Chief Scientific Officer

Founding Team

Michael Midmer

Chief Executive Officer

Executive Team

Zucara Therapeutics Inc. Investors

Notable investors and investment history

Zucara Therapeutics Inc. investors
InvestorRounds
Canadian Glycomics NetworkGrant
Perceptive AdvisorsSeries B, Series A
Helmsley Charitable TrustDebt
National Research Council Canada Industrial Research Assistance ProgramGrant
MitacsGrant
JDRFSeries B, Grant
TIAPAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 7, 2025

    Monthly visitors increased 88% MoM.

  • Jun 2, 2025

    Monthly visitors increased 32% MoM.

Zucara Therapeutics Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Zucara Therapeutics Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Zucara Therapeutics Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersToronto
Employee Range13
Year Founded2015
Last FundingMay 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.